While this selectivity is what drives muscle growth, it also signals the hypothalamic-pituitary-gonadal (HPG) axis to reduce natural testosterone production. While it may not carry the same immediate risks as traditional anabolic steroids, Ligandrol is far from risk-free. Often marketed as a "safer alternative" to anabolic steroids, it is frequently described as selective, mild, and well-tolerated. It can increase lean mass, but it also suppresses natural testosterone production, alters lipid profiles, and carries long-term uncertainty. While it is not considered as hepatotoxic as certain oral anabolic steroids, liver stress is still a legitimate concern. While short-term studies may not capture clinical events, repeated cycles or prolonged exposure may contribute to long-term cardiovascular risk. Increases in lean mass over weeks do not necessarily translate into durable functional improvement or safety over years. Some LGD-4033 users report shedding or recession of hair on the scalp, similar to anabolic steroids. In a randomized clinical trial, LGD-4033 was given to 76 healthy men and produced no notable changes in serum aminotransferases from the following dosages over 21 days (10). SARMs, despite being non-steroidal, still suppress natural testosterone levels due to their aggressive binding to the androgen receptor (22, 23). Thus, low levels of HDL, known as hypoalphalipoproteinemia, increase the risk of myocardial infarction, similar to the extent of anabolic steroids (19, 20). One group of healthy young men received 1 mg/day for 3 weeks and gained 1.21 kg (10). In phase 1 clinical trials, LGD-4033 has produced notable increases in lean muscle mass. Ligandrol is taken orally as a tablet at doses between 0.5 and 2 milligrams. These are vital to your health and gains, and you should not begin without them. It is important to take support supplements during the whole cycle, from day one through completion. It’s recommend that you obtain cycle support supplements that protect the health of your organs, including the liver and kidneys. Dim 3X quickly starts to increase your testosterone levels while decreasing estrogen levels to bring your hormones back into balance. During this time you will experience low testosterone which can lead to you losing most of the gains you made. However, it is possible for individuals to experience deteriorations in health that persist after cycle cessation. Generally, we have found that LGD-4033’s toxic effects are transient and improve post-cycle. LGD-4033 is known to be a less deleterious SARM compared to LGD-3303; however, the difference is due to researchers administering approximately three times higher doses of LGD-3303. There was a dose-proportional increase in LGD-4033 concentrations on days 1 and 21. There were no clinically significant changes in liver enzymes, hematocrit, prostate-specific antigen, or electrocardiogram at any dose. Headache, pain related to muscle biopsy, and dry mouth were the most common events and did not show dose relationship (Supplementary Appendix Table 1). The way that SARMs work is by selectively binding to androgen receptors. Ligandrol is classified as a selective androgen receptor modulator (SARM). Ligandrol was originally developed to treat muscle wasting disorders. Some users on an LGD-4033 cycle may think they’re gaining fat. You might only consider using LGD-4033 in a fat loss cycle when you stack it with another compound – for example, MK677 – to build muscle and burn fat simultaneously to enhance definition. With its primary benefits around muscular gains, LGD-4033 could help you maintain lean muscle when cutting; however, this SARM isn’t known to affect fat loss directly. Even gains in the 5-10lbs range are easily acquired for less hardcore cycles, even if your diet isn’t perfect. As always, you’ll only get out what you put in, but with the right diet and workout program, your gains can be in the 10-15lbs range in a single cycle. The better your diet is, the more you’ll benefit here, but experience has shown that even on a calorie-deficit diet, weightlifters have seen substantial strength gains. LGD-4033 delivers some incredible gains in strength, which can come about even when you’re not consuming a diet that would typically help support such extreme strength. On 22 May 2014, Viking Therapeutics licensed the developmental rights of LGD-4033 from Ligand Pharmaceuticals and intended to advance the compound into mid-to-late-stage clinical trials. By 2012, a phase 2 trial of LGD-4033 for the treatment of muscle wasting related to cancer cachexia, acute rehabilitation (e.g., hip fracture), and acute illness was being prepared by Ligand Pharmaceuticals. On the basis of a favorable preclinical profile, phase 1 clinical trials of LGD-4033 began in 2009. LG is a tricyclic quinoline derivative, and is structurally distinct from arylpropionamide SARMs like andarine and enobosarm (ostarine). It was the first orally active nonsteroidal androgen receptor agonist to be discovered. Levels of LGD-4033 were 3-fold higher at day 21 compared to day 1, indicating significant accumulation with repeated administration. This was a double-blind, placebo-controlled, multiple once-daily dose escalation study of LGD-4033 in healthy men, approved by Boston University’s Institutional Review Board. This dose was selected for FSR study because preclinical data suggested that this dose was the most likely to increase LBM. Here we report the results of a randomized, double-blind, placebo-controlled, ascending-dose study, which evaluated the safety, tolerability, and pharmacokinetics (PK) of LGD-4033 in healthy men. In animal models, LGD-4033 has demonstrated anabolic activity in the muscle, anti-resorptive and anabolic activity in bone, and robust selectivity for muscle versus prostate. Among the various candidate function-promoting anabolic therapies that are in development, androgens are the farthest along in development.
